SEC Comment Letter for Zenlabs Holdings Inc (CIK 0001803705) — Sep 22, 2021
Zenlabs Holdings Inc (CIK 0001803705)
Date: Sept. 22, 2021 · CIK: 0001803705 · Accession: 0000000000-21-011546
AI Filing Summary & Sentiment
File numbers found in text: 024-11635
Letter
United States securities and exchange commission logo September 22, 2021 Kelly Stopher Chief Financial Officer Zenlabs Holdings Inc 7745 Arjons Drive San Diego, CA 92126 Re:Zenlabs Holdings Inc Offering Statement on Form 1-A Filed September 13, 2021 File No. 024-11635 Dear Mr. Stopher: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Lauren Hamill at 303-844-1008 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Arden Anderson
Show Raw Text
United States securities and exchange commission logo
September 22, 2021
Kelly Stopher
Chief Financial Officer
Zenlabs Holdings Inc
7745 Arjons Drive
San Diego, CA 92126
Re:Zenlabs Holdings Inc
Offering Statement on Form 1-A
Filed September 13, 2021
File No. 024-11635
Dear Mr. Stopher:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Lauren Hamill at 303-844-1008 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Arden Anderson